Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB1 | P46663 | 12/20 | 0.48 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | F10 | P00742 | 4/20 | 0.41 |
| ▸ | LSS | P48449 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5628643 | 0.78 | BDKRB1 (0.50) | BDKRB1F10 | |
| SCHEMBL3440370 | 0.77 | BDKRB1 (0.46) | BDKRB1F10 | |
| SCHEMBL4793955 | 0.72 | BDKRB1 (0.49) | BDKRB1F10SMN1; SMN2 | |
| SCHEMBL3440068 | 0.71 | CHRM1 (0.48) | BDKRB1LMNACHRM1 | |
| SCHEMBL4714421 | 0.71 | BDKRB1 (0.48) | BDKRB1F10CHRM1 | |
| SCHEMBL3439976 | 0.71 | CHRM1 (0.47) | F10CHRM1 | |
| SCHEMBL5842753 | 0.70 | BDKRB1 (0.51) | BDKRB1F10 | |
| SCHEMBL13941265 | 0.69 | F10 (0.42) | BDKRB1F10LMNAHTTSMN1; SMN2 | |
| SCHEMBL3440375 | 0.69 | BDKRB1 (0.46) | BDKRB1F10 | |
| SCHEMBL12914413 | 0.69 | USP2 (0.48) | BDKRB1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060217362-A1 | Novel compounds useful for bradykinin B1 receptor antagonism | ELAN PHARMACEUTICALS, INC. | 2006-09-28 | — | — | US | claimed |
| US-20060217362-A1 | Novel compounds useful for bradykinin B1 receptor antagonism | ELAN PHARMACEUTICALS, INC. | 2006-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060217362-A1 | Novel compounds useful for bradykinin B1 receptor antagonism | BDKRB1, BDKRB2, NPBWR1 | BDKRB1 1/4885HDAC3 4193/4885HDAC1 3132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.